Clinical Trial Update: EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma [Phase 1]

View source ↗

Summary

Phase 1 pediatric trial of the EZH2 inhibitor tazemetostat in INI1-negative tumors and synovial sarcoma has completed. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Rhabdoid Tumor of Ovary
• Rhabdoid Tumor
• Synovial Sarcoma

Drugs mentioned

• Tazemetostat (tazemetostat)

Snippet

Sponsor: Epizyme, Inc. | Conditions: Rhabdoid Tumors, INI1-negative Tumors | Phase 1 | Status: COMPLETED | Results posted: 2024-10-03